Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 3/2011

01-03-2011 | Short Communication

Can malignant bowel obstruction in advanced cancer patients be treated at home?

Authors: Giampiero Porzio, Federica Aielli, Lucilla Verna, Brigida Galletti, Ghazaleh Shoja e Razavi, Corrado Ficorella

Published in: Supportive Care in Cancer | Issue 3/2011

Login to get access

Abstract

Eleven advanced cancer patients affected by malignant bowel obstruction (MBO) were treated at home with a combination of octreotide, metoclopramide, morphine, and dexamethasone. In all patients, we observed a prompt control of gastrointestinal symptoms and recovery of bowel movements within 1–5 days. Based on our results, a combination of drugs with different mechanisms of action allows an effective and safe treatment for MBO at home. Further studies with larger number of patients are warranted to confirm these preliminary data.
Literature
1.
Mercadante S, Ferrera P, Villari P et al (2004) Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage 28:412–416PubMedCrossRef
2.
Maltoni M, Nanni O, Pirovano M et al (1999) Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian multicentric study group on palliative care. J Pain Symptom Manage 17:240–247PubMedCrossRef
3.
Ripamonti C, Twycross R, Baines M et al (2001) Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Supp Care Cancer 9:223–233CrossRef
4.
Ripamonti C, Bruera E (2002) Palliative mangement of malignant bowel obstruction. Int J Gynecol Cancer 12:135–143PubMedCrossRef
5.
Anonymous (2006) The challenge of treating malignant bowel ostruction. J Support Oncol 4:83–84
6.
Ripamonti CI, Eassson AM, Gerdes H (2008) Management of malignant bowel obstruction. Eur J Cancer 44:1005–1015CrossRef
7.
Mercadante S (1995) Tolerability of continous subcutaneous ocreotide used in combination with other drugs. J Palliat Care 11:1s4
8.
Mercadante S (1995) Bowel obstruction in home-care patients: 4 years experience. Support Care Cancer 3:190–193PubMedCrossRef
9.
Mercadante S, Ripamonti C, Casuccio A et al (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Supp Care Cancer 8:188–191CrossRef
Metadata
Title
Can malignant bowel obstruction in advanced cancer patients be treated at home?
Authors
Giampiero Porzio
Federica Aielli
Lucilla Verna
Brigida Galletti
Ghazaleh Shoja e Razavi
Corrado Ficorella
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-1009-4

Other articles of this Issue 3/2011

Supportive Care in Cancer 3/2011 Go to the issue

Original Article

Patients’ views about causes and preferences for the management of cancer-related fatigue—a case for non-congruence with the physicians?

Review Article

Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials

Original Article

Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer

Short Communication

The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study

Original Article

An evaluation of the factors that affect the health-related quality of life of children following myelosuppressive chemotherapy

Original Article

Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits